C12N 2760/10021
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2760/10021 (Viruses as such) appears on 12 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 12
- Published applications
- 20
- Assignees
- 7
- Inventors
- 63
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2016 | 0 | 3 |
| 2017 | 1 | 1 |
| 2018 | 2 | 2 |
| 2019 | 0 | 3 |
| 2020 | 2 | 0 |
| 2021 | 0 | 2 |
| 2022 | 1 | 2 |
| 2023 | 3 | 1 |
| 2024 | 1 | 3 |
| 2025 | 1 | 3 |
| 2026 | 1 | 0 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Virus particles for therapeutic purposes18 Aug 2026US 12,708,654 B2Abalos Therapeutics GmbH
- Administering a lymphocytic choriomeningtitis virus (LCMV) with improved tumor regression properties9 Sep 2025US 12,409,217 B2Abalos Therapeutics GmbH
- Method for producing an antitumoral arenavirus as well as arenavirus mutants29 Oct 2024US 12,129,281 B2Abalos Therapeutics GmbH
- Method of enhancing innate immune responses against a tumor comprising administering lymphocytic choriomeningitis virus (LCMV)31 Oct 2023US 11,801,294 B2Abalos Therapeutics GmbH
- Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity2 May 2023US 11,638,751 B2Institut Pasteur
- Live attenuated junin virus and related compositions and methods3 Jul 2025US 2025/0213672 A1Utah State University
- Method for producing an antitumoral arenavirus as well as arenavirus mutants17 Apr 2025US 2025/0122244 A1Abalos Therapeutics GmbH
- Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies6 Mar 2025US 2025/0073324 A1Hookipa Biotech GmbH
- Veterinary viral vector29 Aug 2024US 2024/0285748 A1
- Arenaviruses for use in the treatment and/or prevention of tumors and method for producing arenaviruses with (im-proved) tumor-regression properties1 Aug 2024US 2024/0252611 A1Abalos Therapeutics GmbH
Most cited
By later US patents
- CMV vaccines11US 10,111,945 B2Hookipa Biotech GmbH · 2018
- Anti-mycobacterial vaccines8US 9,809,801 B2Universite De Geneve · 2017
- Tri-segmented arenaviruses as vaccine vectors7US 10,722,564 B2Universite De Geneve · 2020
- CMV vaccines1US 11,554,169 B2Hookipa Biotech GmbH · 2023
- Method for producing an antitumoral arenavirus as well as arenavirus mutants1US 12,129,281 B2Abalos Therapeutics GmbH · 2024